Label expansion approved in Europe for Darzalex, triple-drug combo in MM treatment
Janssen, a division of Johnson & Johnson, has gained European regulators' approval for the label expansion of its combo therapy Darzalex, or daratumumab, combined with bortezomib, thalidomide and dexamethasone, or VTd. The European Commission approved Janssen's marketing authorization for the Darzalex-VTd regimen to treat newly diagnosed multiple myeloma patients qualified to undergo an autologous stem cell transplant. PMLive (UK) (1/21)
Read full article now.
Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!